To investigate the clinical significance of urine protein quantitative test UPCR (ratio of urinary protein amount measured and creatinine concentration in urine) when anti-angiogenesis inhibitors are used.
From January 2018 to December 2018, a survey was conducted based on the medical records of gastric cancer and colorectal cancer cases with urine protein qualitative value test (QV) of 2+ or higher during the use of anti-angiogenesis inhibitors at 9 institutions participating in Onconephrology Consortium. The primary endpoint was the ratio of UPCR worst value less than 2 (Low UPCR) in QV 2+ cases. The secondary endpoints were comparison of Low UPCR and UPCR worst value2 or higher (High UPCR), the use status of angiogenesis inhibitors, changes in urine protein test values (qualitative/quantitative), subsequent treatment information, and patient background factors and other relationships.
Among 71 cases enrolled, the proportion of Low UPCR in QV 2+ cases (n=53) was 66% (n=35). In a comparison between Low (n=36) and High UPCR cases (n=24), High UPCR tended to occur in cases of heavy body weight, and its cut-off value was 52.45 kg (OR 4.25, 95%CI 1.30-13.86, p=0.017). A significant correlation was also observed between UPCR levels and the single dose of bevacizumab (p=0.033) or ramcirumab (p=0.018).
The relationship between UPCR levels and body weight or single dose was shown, but there is a possibility that physical disparity and the amount of creatinine excretion may have an effect.
The authors.
Has not received any funding.
M. Nakamura: Honoraria (self): Daiichi Sankyo; Honoraria (self): Lilly; Honoraria (self): Chugai; Honoraria (self): Mochida; Honoraria (self): Bristol Myers Squibb; Honoraria (self): Taiho. T. Funakoshi: Research grant/Funding (institution), TF belongs to an endowed department sponsored partly by Chugai Pharmaceutical Co., Ltd.: Chugai. E. Baba: Honoraria (self): Lilly; Research grant/Funding (institution): Taiho; Research grant/Funding (institution): Chugai. Y. Mihara: Honoraria (self): Chugai. M. Muto: Honoraria (self), Research grant/Funding (institution), MM belongs to an endowed department sponsored partly by Chugai Pharmaceutical Co., Ltd.: Chugai; Research grant/Funding (self): Sanofi. M. Yanagita: Honoraria (self): Chugai; Honoraria (self): Kyowa Hakko Kirin; Research grant/Funding (institution): Kyowa Hakko Kirin; Research grant/Funding (institution): Tanabe Mitsubishi; Research grant/Funding (institution): Nippon Boehringer Ingelheim; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Baxter; Research grant/Funding (institution): Chugai; Research grant/Funding (institution): Kyowa Hakko Kirin; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): Takeda. All other authors have declared no conflicts of interest.